Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts

Molecular Oncology

Volumn 6, Issue 4, 2012, Pages 418-427

  Lindholm, Evita M ^a   Kristian, Alexandr ^a   Nalwoga, Hawa ^b   Krüger, Kristi ^b   Nygård, Ståle ^c   Akslen, Lars A ^b   Mælandsmo, Gunhild M ^a,d   Engebraaten, Olav ^a,e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c Bioinformatics Core Facility   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Angiogenesis; Bevacizumab; Breast cancer; Kinase activity; Tumor vasculature; Xenografts

Indexed keywords

BEVACIZUMAB; DOXORUBICIN; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DENSITY; DRUG EFFECT; ENZYME ACTIVITY; MICROVASCULATURE; MONOTHERAPY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

EID: 84864315105     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.03.006     Document Type: Article

References (39)

1. Arteaga C.L., Johnson M.D., Todderud G., Coffey R.J., Carpenter G., Page D.L. Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:10435-10439.
2. Bear H.D., Tang G., Rastogi P., Geyer C.E., Robidoux A., Atkins J.N., Baez-Diaz L., Brufsky A.M., Mehta R.S., Fehrenbacher L., Young J.A., Senecal F.M., Gaur R., Margolese R.G., Adams P.T., Gross H.M., Costantino J.P., Swain S.M., Mamounas E.P., Wolmark N. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. New England Journal of Medicine 2012, 366:310-320.
3. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society 1995, 57:289-300.
4. Bergamaschi A., Hjortland G.O., Triulzi T., Sorlie T., Johnsen H., Ree A.H., Russnes H.G., Tronnes S., Maelandsmo G.M., Fodstad O., Borresen-Dale A.L., Engebraaten O. Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Molecular Oncology 2009, 3:469-482.
5. Berns E.M., Klijn J.G., Look M.P., Grebenchtchikov N., Vossen R., Peters H., Geurts-Moespot A., Portengen H., van Staveren I.L., Meijer-van Gelder M.E., Bakker B., Sweep F.C., Foekens J.A. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Clinical Cancer Research 2003, 9:1253-1258.
6. Borrello M.G., Alberti L., Arighi E., Bongarzone I., Battistini C., Bardelli A., Pasini B., Piutti C., Rizzetti M.G., Mondellini P., Radice M.T., Pierotti M.A. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Molecular and Cellular Biology 1996, 16:2151-2163.
7. Chang J.-S., Iwashita S., Lee Y.H., Kim M.J., Ryu S.H., Suh P.-G. Transformation of rat fibroblasts by phospholipase C-γ1 overexpression is accompanied by tyrosine dephosphorylation of paxillin. FEBS Letters 1999, 460:161-165.
8. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England Journal of Medicine 2004, 350:2335-2342.
9. Husain D., Meyer R., Mehta M., Pfeifer W.M., Chou E., Navruzbekov G., Ahmed E., Rahimi N. Role of c-Cbl dependent regulation of phospholipase C gamma 1 activation in Experimental Choroidal Neovascularization. Investigative Ophthalmology & Visual Science 2010, 51:6803-6809.
10. Ito N., Wernstedt C., Engstrom U., Claesson-Welsh L. Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation sites and binding of SH2 domain-containing molecules. The Journal of Biological Chemistry 1998, 273:23410-23418.
11. Iwama A., Yamaguchi N., Suda T. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family. The EMBO Journal 1996, 15:5866-5875.
12. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62. New York, NY.
13. Jayson, G.C., Haas, Sd, Delmar, P., Miles, D.W., Shah, M.A., Cutsem, E.V., Carmeliet, P., Hegde, P., Wild, N., Scherer, S.J., 2011. Evaluation of plasma VEGFA as a potential predictive pan-tumour biomarker for bevacizumab. 2011 European Multidisciplinary Cancer Congress Abstract 804.
14. Kassis J., Moellinger J., Lo H., Greenberg N.M., Kim H.G., Wells A. A role for phospholipase C-gamma-mediated signaling in tumor cell invasion. Clinical Cancer Research 1999, 5:2251-2260.
15. Linderholm B.K., Hellborg H., Johansson U., Elmberger G., Skoog L., Lehtio J., Lewensohn R. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Annals of Oncology 2009, 20:1639-1646.
16. Machide M., Kamitori K., Kohsaka S. Hepatocyte growth factor-induced differential activation of phospholipase cgamma 1 and phosphatidylinositol 3-kinase is regulated by tyrosine phosphatase SHP-1 in astrocytes. The Journal of Biological Chemistry 2000, 275:31392-31398.
17. Manders P., Beex L.V., Tjan-Heijnen V.C., Geurts-Moespot J., Van Tienoven T.H., Foekens J.A., Sweep C.G. The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. British Journal of Cancer 2002, 87:772-778.
18. Markova B., Albers C., Breitenbuecher F., Melo J.V., Brummendorf T.H., Heidel F., Lipka D., Duyster J., Huber C., Fischer T. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway. Oncogene 2010, 29:739-751.
19. Marrero M.B., Venema R.C., Ma H., Ling B.N., Eaton D.C. Erythropoietin receptor-operated Ca2+ channels: activation by phospholipase C-gamma 1. Kidney International 1998, 53:1259-1268.
20. Mason I. The RET receptor tyrosine kinase: activation, signalling and significance in neural development and disease. In. Pharm Acta Helv 2000, Vol. 74:261-264.
21. Miles D.W., Chan A., Dirix L.Y., Cortes J., Pivot X., Tomczak P., Delozier T., Sohn J.H., Provencher L., Puglisi F., Harbeck N., Steger G.G., Schneeweiss A., Wardley A.M., Chlistalla A., Romieu G. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of Clinical Oncology 2010, 28:3239-3247.
22. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., Shenkier T., Cella D., Davidson N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. The New England Journal of Medicine 2007, 357:2666-2676.
23. Nel A.E., Gupta S., Lee L., Ledbetter J.A., Kanner S.B. Ligation of the T-cell antigen receptor (TCR) induces association of hSos1, ZAP-70, phospholipase C-gamma 1, and other phosphoproteins with Grb2 and the zeta-chain of the TCR. The Journal of Biological Chemistry 1995, 270:18428-18436.
24. Pocock T.M., Bates D.O. In vivo mechanisms of vascular endothelial growth factor-mediated increased hydraulic conductivity of Rana capillaries. The Journal of Physiology 2001, 534:479-488.
25. Poulin B., Sekiya F., Rhee S.G. Differential roles of the Src homology 2 domains of phospholipase C-gamma1 (PLC-gamma1) in platelet-derived growth factor-induced activation of PLC-gamma1 in intact cells. The Journal of Biological Chemistry 2000, 275:6411-6416.
26. Ren H.Y., Komatsu N., Shimizu R., Okada K., Miura Y. Erythropoietin induces tyrosine phosphorylation and activation of phospholipase C-gamma 1 in a human erythropoietin-dependent cell line. The Journal of Biological Chemistry 1994, 269:19633-19638.
27. Rouzier R., Perou C.M., Symmans W.F., Ibrahim N., Cristofanilli M., Anderson K., Hess K.R., Stec J., Ayers M., Wagner P., Morandi P., Fan C., Rabiul I., Ross J.S., Hortobagyi G.N., Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clinical Cancer Research 2005, 11:5678-5685.
28. Sala G., Dituri F., Raimondi C., Previdi S., Maffucci T., Mazzoletti M., Rossi C., Iezzi M., Lattanzio R., Piantelli M., Iacobelli S., Broggini M., Falasca M. Phospholipase Cgamma1 is required for metastasis development and progression. Cancer Research 2008, 68:10187-10196.
29. Tomlinson M.G., Kane L.P., Su J., Kadlecek T.A., Mollenauer M.N., Weiss A. Expression and function of Tec, Itk, and Btk in lymphocytes: evidence for a unique role for Tec. Molecular and Cellular Biology 2004, 24:2455-2466.
30. Volk L.D., Flister M.J., Bivens C.M., Stutzman A., Desai N., Trieu V., Ran S. Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia 2008, 10:613-623. New York, NY.
31. von Minckwitz G., Eidtmann H., Rezai M., Fasching P.A., Tesch H., Eggemann H., Schrader I., Kittel K., Hanusch C., Kreienberg R., Solbach C., Gerber B., Jackisch C., Kunz G., Blohmer J.-U., Huober J., Hauschild M., Fehm T., Muller B.M., Denkert C., Loibl S., Nekljudova V., Untch M. Neoadjuvant chemotherapy and bevacizumab for HER2-Negative breast cancer. New England Journal of Medicine 2012, 366:299-309.
32. Weber J.R., Bell G.M., Han M.Y., Pawson T., Imboden J.B. Association of the tyrosine kinase LCK with phospholipase C-gamma 1 after stimulation of the T cell antigen receptor. The Journal of Experimental Medicine 1992, 176:373-379.
33. Williams B.L., Irvin B.J., Sutor S.L., Chini C.C., Yacyshyn E., Bubeck Wardenburg J., Dalton M., Chan A.C., Abraham R.T. Phosphorylation of Tyr319 in ZAP-70 is required for T-cell antigen receptor-dependent phospholipase C-gamma1 and Ras activation. The EMBO Journal 1999, 18:1832-1844.
34. Workman P., Aboagye E.O., Balkwill F., Balmain A., Bruder G., Chaplin D.J., Double J.A., Everitt J., Farningham D.A., Glennie M.J., Kelland L.R., Robinson V., Stratford I.J., Tozer G.M., Watson S., Wedge S.R., Eccles S.A. Guidelines for the welfare and use of animals in cancer research. British Journal of Cancer 2010, 102:1555-1577.
35. Xie Z., Chen Y., Liao E.Y., Jiang Y., Liu F.Y., Pennypacker S.D. Phospholipase C-gamma1 is required for the epidermal growth factor receptor-induced squamous cell carcinoma cell mitogenesis. Biochemical and Biophysical Research Communications 2010, 397:296-300.
36. Xie Z., Peng J., Pennypacker S.D., Chen Y. Critical role for the catalytic activity of phospholipase C-gamma1 in epidermal growth factor-induced cell migration. Biochemical and Biophysical Research Communications 2010, 399:425-428.
37. Yanagisawa M., Yorozu K., Kurasawa M., Nakano K., Furugaki K., Yamashita Y., Mori K., Fujimoto-Ouchi K. Bevacizumab improves the delivery and efficacy of paclitaxel. Anti-cancer Drugs 2010, 21:687-694.
38. Yang J.M., Vassil A.D., Hait W.N. Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway. Molecular Pharmacology 2001, 60:674-680.
39. Yang S.X., Steinberg S.M., Nguyen D., Wu T.D., Modrusan Z., Swain S.M. Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clinical Cancer Research 2008, 14:5893-5899.